M
Michael F. McDermott
Researcher at University of Leeds
Publications - 153
Citations - 16117
Michael F. McDermott is an academic researcher from University of Leeds. The author has contributed to research in topics: Familial Mediterranean fever & Tumor necrosis factor alpha. The author has an hindex of 55, co-authored 148 publications receiving 14562 citations. Previous affiliations of Michael F. McDermott include Royal London Hospital & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Hereditary periodic fever syndromes.
TL;DR: Hereditary periodic fever syndromes are defined by recurrent attacks of generalised inflammation for which no infectious or auto-immune cause can be identified and results of treatment with recombinant TNF-receptor analogues are promising.
Journal ArticleDOI
Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes
TL;DR: The long-term safety of all targeted anti-IL-1 therapies in CAPS remains an unanswered question owing to the relatively short clinical experience with these agents; as canakinumab produces sustained IL-1 suppression, vigilance is necessary to diagnose the development of adverse events, especially any associated infections.
Journal ArticleDOI
Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis
Lylia Ouboussad,Lylia Ouboussad,L Hunt,L Hunt,Elizabeth M A Hensor,Elizabeth M A Hensor,Jackie L. Nam,Jackie L. Nam,Nicholas A. Barnes,Nicholas A. Barnes,Nicholas A. Barnes,Paul Emery,Paul Emery,Michael F. McDermott,Michael F. McDermott,Maya H Buch,Maya H Buch +16 more
TL;DR: This first study to use matched serum samples and a comprehensive miRNA array approach to identify in particular, three miRNAs associated with progression from systemic autoimmunity to RA inflammation, indicating a potential biomarker role for at-risk individuals.
Journal ArticleDOI
NOD-like receptors and inflammation
TL;DR: The role played by NLRs in a variety of inflammatory diseases is discussed and the remarkable success to date of these therapeutic agents in treating some of the disorders associated with aberrant NLR function is described.
Journal ArticleDOI
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
TL;DR: The selective blockade of IL-1β, with anakinra (IL-1 receptor antagonist), not only provided supportive evidence for the role of IL -1β in CAPS, but also demonstrated the efficacy of targeting IL- 1β for treatment of these conditions.